Posted by Michael Wonder on 03 Jan 2023
Pertuzumab and pertuzumab with trastuzumab in breast cancer: now a minor additional clinical benefit
2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of time - current early benefit assessments show how sensible it is to set a time limit for certain indications.
Pertuzumab in free and fixed combination with trastuzumab is approved, among other things, for the adjuvant therapy of patients with HER2 positive, early breast cancer, in whom a high risk for a relapse. The IQWiG has already examined this supportive therapy for the patient group mentioned in the past as part of early benefit assessments.
